rosuvastatinWhat was measured
Measured, with no finding
251 endpoints
Show what was measuredHide what was measured
5-year NNT to prevent 1 primary endpoint
The 5-year NNT to prevent 1 primary endpoint was calculated at 36 in women, 22 in men, and 25 when combined
PMID 20176986 · one of two readings recorded this
5-year NNT to prevent 1 primary endpoint
The 5-year NNT to prevent 1 primary endpoint was calculated at 36 in women, 22 in men, and 25 when combined
PMID 20176986 · one of two readings recorded this
All-cause death (hazard ratio)
no effect
The HR for all cause death was similarly reduced for women (HR 0.77, 95% CI 0.55–1.06) and men (HR 0.82, 95% CI 0.66–1.03)
PMID 20176986 · one of two readings recorded this
All-cause death (hazard ratio)
no effect
The HR for all cause death was similarly reduced for women (HR 0.77, 95% CI 0.55–1.06) and men (HR 0.82, 95% CI 0.66–1.03)
PMID 20176986 · one of two readings recorded this
Baseline hsCRP
unclear, p = 0.001
Women had higher concentrations of hsCRP (4.6 vs 4.1 mg/L, respectively, P<0.001)
PMID 20176986 · one of two readings recorded this
Baseline LDL cholesterol
no effect
Women and men had similar baseline LDL cholesterol (109 and 108 mg/dL, respectively)
PMID 20176986 · one of two readings recorded this
CVD events, statin trials in women (meta-analysis, relative risk)
decreases, p = 0.001, n = 13154
The summary RR for the 3 trials was 0.63 (0.49–0.82), P<0.001, P for heterogeneity 0.56
PMID 20176986 · one of two readings recorded this
CVD events, statin trials in women (meta-analysis, relative risk)
decreases, p = 0.03
the summary RR was unchanged (0.82, 95% CI 0.69–0.98), P=0.03
PMID 20176986 · one of two readings recorded this
CVD events, statin trials in women (meta-analysis, relative risk)
no effect, p = 0.11
the summary RR was similar but not statistically significant, 0.79 (95% CI 0.59–1.05), P=0.11, P for heterogeneity=0.053
PMID 20176986 · one of two readings recorded this
HDL cholesterol change
increases
HDL cholesterol increased by 3 mg/dL and 1 mg/dL in women on rosuvastatin and placebo, respectively
PMID 20176986 · one of two readings recorded this
hsCRP median change
decreases
At 12-month follow-up, the median change in hsCRP concentrations in women was −1.8 mg/L (39%) with rosuvastatin and −0.6 mg/L (13%) with placebo
PMID 20176986 · one of two readings recorded this
LDL cholesterol median change
decreases
In women, the median change in LDL cholesterol was −51 mg/dL (47%) on rosuvastatin and +4 mg/dL (4%) on placebo
PMID 20176986 · one of two readings recorded this
Physician-reported diabetes
no effect, p = 0.24
compared with men (1.36 vs 1.20 per 100 person-years, respectively, HR 1.14, 95% CI 0.91–1.43, P=0.24)
PMID 20176986 · one of two readings recorded this
Physician-reported diabetes
increases, p = 0.008
a higher incidence of physician-reported diabetes was observed in women treated with rosuvastatin vs placebo (1.53 vs 1.03 per 100 person-years, respectively, HR 1.49, 95% CI 1.11–2.01, P=0.008)
PMID 20176986 · one of two readings recorded this
Primary composite CVD endpoint absolute rate
decreases
the absolute rates (per 100 person-years) of the primary endpoint in rosuvastatin and placebo were lower in women (0.56 and 1.04, respectively) than men (0.88 and 1.54, respectively)
PMID 20176986 · one of two readings recorded this
Primary composite CVD endpoint absolute rate
decreases
the absolute rates (per 100 person-years) of the primary endpoint in rosuvastatin and placebo were lower in women (0.56 and 1.04, respectively) than men (0.88 and 1.54, respectively)
PMID 20176986 · one of two readings recorded this
Primary composite CVD endpoint (hazard ratio)
decreases, p = 0.001, n = 11001
and men (0.58, 95% CI 0.45–0.73, P<0.001
PMID 20176986 · one of two readings recorded this
Primary composite CVD endpoint (hazard ratio)
decreases, p = 0.002, n = 6801
the relative risk reduction with rosuvastatin was similar and statistically significant in both women (hazard ratio 0.54, 95% CI 0.37–0.80, P=0.002)
PMID 20176986 · one of two readings recorded this
Primary endpoint absolute rate
decreases
The absolute event rates (per 100 person-years) were lower in women with scores 5 to 10% (0.42 in rosuvastatin and 0.96 in placebo) compared with women with scores >10% (1.28 and 2.23, respectively)
PMID 20176986 · one of two readings recorded this
Primary endpoint absolute rate
decreases
The absolute event rates (per 100 person-years) were lower in women with scores 5 to 10% (0.42 in rosuvastatin and 0.96 in placebo) compared with women with scores >10% (1.28 and 2.23, respectively)
PMID 20176986 · one of two readings recorded this
Primary endpoint (hazard ratio)
decreases, n = 829
HRs 0.20, 95% CI 0.06–0.69 and 0.63, 95% CI 0.41–0.96, respectively, P for interaction 0.07
PMID 20176986 · one of two readings recorded this
Primary endpoint (hazard ratio)
decreases, n = 1646
Women with Framingham risk scores of 5 to 10% (N=2,525) and >10% (N=1,646) had similar and significant proportional reduction in events (HRs 0.44, 95% CI 0.22–0.89, and 0.57, 95% CI 0.34–0.97)
PMID 20176986 · one of two readings recorded this
Primary endpoint (hazard ratio)
decreases, n = 2525
Women with Framingham risk scores of 5 to 10% (N=2,525) and >10% (N=1,646) had similar and significant proportional reduction in events (HRs 0.44, 95% CI 0.22–0.89, and 0.57, 95% CI 0.34–0.97)
PMID 20176986 · one of two readings recorded this
Primary endpoint (hazard ratio)
no effect
HRs 0.35, 95% CI 0.19–0.65, and 0.77, 95% CI 0.46–1.30, respectively, P for interaction 0.06
PMID 20176986 · one of two readings recorded this
Primary endpoint (hazard ratio)
decreases
HRs 0.20, 95% CI 0.06–0.69 and 0.63, 95% CI 0.41–0.96, respectively, P for interaction 0.07
PMID 20176986 · one of two readings recorded this
Primary endpoint (hazard ratio)
decreases
HRs 0.35, 95% CI 0.19–0.65, and 0.77, 95% CI 0.46–1.30, respectively, P for interaction 0.06
PMID 20176986 · one of two readings recorded this
Primary endpoint ratio of relative hazards, women vs men
no effect
The HR and 95% CI for the ratio of the relative hazards for treatment in women and men for the primary endpoint were 0.94 (0.60–1.49)
PMID 20176986 · one of two readings recorded this
Primary endpoint treatment-by-sex interaction
no effect, p = 0.8
The P-value for a treatment-by-sex interaction using a sex-stratified Cox proportional hazard model was non-significant (P=0.80)
PMID 20176986 · one of two readings recorded this
Revascularization/unstable angina (hazard ratio)
decreases
than for men (HR 0.63, 95% CI 0.46–0.85), P for heterogeneity 0.01
PMID 20176986 · one of two readings recorded this
Revascularization/unstable angina (hazard ratio)
decreases
Women had significant reduction in revascularization/unstable angina (HR 0.24, 95% CI 0.11–0.51)
PMID 20176986 · one of two readings recorded this
Total mortality, statin trials in women (meta-analysis, relative risk)
no effect, p = 0.21, n = 13154
The summary RR for the 3 exclusively primary prevention trials (N=13,154 women, 216 deaths) that reported sex-specific total mortality was 0.78 (95% CI 0.53–1.15), P=0.21
PMID 20176986 · one of two readings recorded this
Triglycerides change
decreases
Triglycerides were reduced by 17 mg/dL (14%) in women on rosuvastatin with no change on placebo
PMID 20176986 · one of two readings recorded this
Blood HDL-cholesterol
increases
There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%
PMID 25415541 · one of two readings recorded this
HDL-cholesterol, rosuvastatin overall effect, trials pooled
increases, overall HDL increase of 7%
Not recorded as a finding: Sentence joins a no-dose-response finding to an overall 7% increase in one clause and gives no interval or test, so no single clean direction span; also pools before-and-after trials
There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%.
PMID 25415541 · one of two readings recorded this
LDL-cholesterol and HDL-cholesterol change on rosuvastatin 1 to 80 mg/day, pooled by generic inverse variance across 18 placebo-controlled and 90 before-and-after trials
decreases, LDL-cholesterol decreases of 46% to 55% at 10 to 40 mg/day
Not recorded as a finding: the result compares a group with itself, not with a control
Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method.
PMID 25415541 · one of two readings recorded this
LDL-cholesterol decrease
decreases, n = 19596
Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method
PMID 25415541 · one of two readings recorded this
Withdrawals due to adverse effects (WDAEs)
no effect
WDAEs were not statistically different between rosuvastatin and placebo in 10 of 18 of these short-term trials (risk ratio 0.84; 95% confidence interval 0.48 to 1.47)
PMID 25415541 · one of two readings recorded this
CI-AKI heterogeneity (I2)
no effect, p = 0.22
No significant heterogeneity existed across studies (I2 = 30%, P = 0.22)
PMID 26222855 · one of two readings recorded this
CI-AKI incidence
decreases, p = 0.001, n = 4045
Patients receiving rosuvastatin had a 51% lower risk of CI-AKI compared with controls based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001)
PMID 26222855 · one of two readings recorded this
CI-AKI incidence
no effect, p = 0.55
However, when including CKD patients undergoing elective cardiac catheterization, rosuvastatin treatment showed no effect on preventing CI-AKI (I2 = 0%, OR = 0.81, 95% CI = 0.41–1.61, P = 0.55)
PMID 26222855 · one of two readings recorded this
CI-AKI incidence
decreases, p = 0.04
Analysis of the subgroup of patients with CKD indicated that rosuvastatin treatment was beneficial for preventing CI-AKI compared to controls (I2 = 8%, OR = 0.57, 95% CI = 0.34–0.96, P = 0.04)
PMID 26222855 · one of two readings recorded this
CI-AKI incidence
decreases, p = 0.001
The result indicated that studies with Jadad score ≥3 had significantly reduced CI-AKI (OR = 0.53, 95% CI, 0.38–0.73, P < 0.001)
PMID 26222855 · one of two readings recorded this
incidence of contrast-induced acute kidney injury (CI-AKI), defined as an absolute SCr rise of 0.5 mg/dL or 25% from baseline within 72 hours of contrast; no named KDIGO/AKIN/RIFLE criteria set
decreases, OR 0.49, 95% CI 0.37-0.66
Not recorded as a finding: the paper never states the instrument the node requires
Patients receiving rosuvastatin had a 51% lower risk of CI-AKI compared with controls based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001).
PMID 26222855 · one of two readings recorded this
incidence of contrast-induced acute kidney injury, defined as SCr rise of at least 0.5 mg/dL or 25% from baseline within 72 hours, rosuvastatin pretreatment versus placebo, pooled OR
decreases, OR = 0.49, 95% CI = 0.37–0.66
Not recorded as a finding: a node exists but the paper states a different instrument or population
Patients receiving rosuvastatin had a 51% lower risk of CI-AKI compared with controls based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001).
PMID 26222855 · one of two readings recorded this
Major adverse cardiovascular events (MACEs)
unclear, p = 0.08
The incidence of MACEs was only reported in 3 trials, but the trend indicated that rosuvastatin treatment reduced MACEs compared to controls (I2 = 0%, OR = 0.62, 95% CI = 0.36–1.07, P = 0.08)
PMID 26222855 · one of two readings recorded this
Publication bias (Egger's test), CI-AKI
no effect, p = 0.231
the result of Egger's test demonstrated no obvious publication bias among the included trials for CI-AKI (P = 0.231) or MACE (P = 0.324)
PMID 26222855 · one of two readings recorded this
Publication bias (Egger's test), MACE
no effect, p = 0.324
the result of Egger's test demonstrated no obvious publication bias among the included trials for CI-AKI (P = 0.231) or MACE (P = 0.324)
PMID 26222855 · one of two readings recorded this
death during follow-up (event counts)
no effect, p = 0.09
Death | 7(0.7 %) | 15(1.6 %) | 0.09
PMID 26306625 · one of two readings recorded this
death during follow-up (event counts)
no effect, p = 0.06
Death | 9(0.7 %) | 18(1.5 %) | 0.06
PMID 26306625 · one of two readings recorded this
death during follow-up (event counts)
no effect, p = 0.05
Death | 8(0.7 %) | 17(1.5 %) | 0.05
PMID 26306625 · one of two readings recorded this
death during follow-up (event counts)
no effect, p = 0.3
Death | 1(0.4 %) | 2(1.2 %) | 0.3
PMID 26306625 · one of two readings recorded this
death during follow-up (event counts)
no effect, p = 0.42
Death | 2(0.6 %) | 3(1.0 %) | 0.42
PMID 26306625 · one of two readings recorded this
death during follow-up (event counts)
no effect, p = 0.09
Death | 7(0.7 %) | 15(1.6 %) | 0.09
PMID 26306625 · one of two readings recorded this
MACE during follow-up (event counts)
decreases, p = 0.0001
MACE | 33(3.5 %) | 72(7.6 %) | <0.0001
PMID 26306625 · one of two readings recorded this
MACE during follow-up (event counts)
decreases, p = 0.00001
MACE | 45(3.5 %) | 94(7.6 %) | <0.00001
PMID 26306625 · one of two readings recorded this
MACE during follow-up (event counts)
decreases, p = 0.00001
MACE | 41(3.4 %) | 90(8.0 %) | <0.00001
PMID 26306625 · one of two readings recorded this
MACE during follow-up (event counts)
decreases, p = 0.01
MACE | 6(2.4 %) | 14(8.4 %) | 0.01
PMID 26306625 · one of two readings recorded this
MACE during follow-up (event counts)
decreases, p = 0.02
MACE | 12(3.3 %) | 22(7.7 %) | 0.02
PMID 26306625 · one of two readings recorded this
MACE during follow-up (event counts)
decreases, p = 0.0001
MACE | 35(3.7 %) | 76(8.0 %) | <0.0001
PMID 26306625 · one of two readings recorded this
MACE, pooled
decreases, p = 0.0001
a 58 % relative reduction in MACE for ACS patients (OR = 0.42, 95 % CI: 0.27-0.65, P < 0.0001; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
MACE, pooled
decreases, p = 0.00001
a 60 % relative reduction of MACE in all the enrolled patients (OR = 0.40, 95 % CI: 0.27-0.58, P < 0.00001; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
MACE, pooled
decreases, p = 0.01
a 72 % relative reduction in the previous statin therapy group (OR = 0.28, 95 % CI: 0.10-0.73, P = 0.01; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
MACE, pooled
decreases, p = 0.02
RSV preloading before PCI lead to a 58 % relative reduction in MACE for stable angina patients (OR = 0.42, 95 % CI: 0.21-0.87, P = 0.02; I2 = 10 %)
PMID 26306625 · one of two readings recorded this
MACE, pooled
decreases, p = 0.0001
a 58 % relative reduction in the statin naïve group (OR = 0.42, 95 % CI: 0.28-0.64, P < 0.0001; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
major adverse cardiac events (MACE), pooled
decreases, p = 0.00001
The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, P < 0.00001; Fig. 4)
PMID 26306625 · one of two readings recorded this
major adverse cardiac events (mortality, spontaneous MI, target vessel revascularization) during follow-up; also peri-procedural myocardial injury and post-PCI TIMI flow grade 3; high-dose rosuvastatin preloading before PCI, controls mixed placebo, no statin and lower-dose rosuvastatin
decreases, OR 0.42, 95% CI 0.29-0.61
Not recorded as a finding: this platform holds no node for the endpoint
The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, P < 0.00001; Fig. 4).
PMID 26306625 · one of two readings recorded this
major adverse cardiac events, peri-procedural myocardial injury and post-PCI TIMI flow grade 3, high-dose rosuvastatin preloading versus control (placebo, no statin, or low-dose rosuvastatin), pooled OR
decreases, OR = 0.42, 95 % CI: 0.29-0.61
Not recorded as a finding: the comparison was against another active treatment
The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, P < 0.00001; Fig. 4).
PMID 26306625 · one of two readings recorded this
peri-procedural myocardial injury (PMI), pooled
decreases, p = 0.0001
The overall outcome for PMI showed that RSV preloading lead to a 60 % relative reduction in PMI (OR = 0.40, 95 % CI: 0.25-0.63, P < 0.0001; Fig. 5)
PMID 26306625 · one of two readings recorded this
PMI, pooled
decreases, p = 0.0001
a 57 % reduction in PMI for ACS patients (OR = 0.43, 95 % CI: 0.29-0.65, P < 0.0001; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
PMI, pooled
decreases, p = 0.00001
a 67 % relative reduction of PMI in all the enrolled patients (OR = 0.33, 95 % CI: 0.25-0.45, P < 0.00001; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
PMI, pooled
decreases, p = 0.0001
a 69 % relative reduction in the previous statin therapy group (OR = 0.31, 95 % CI: 0.17-0.55, P < 0.0001; I2 = 39 %)
PMID 26306625 · one of two readings recorded this
PMI, pooled
decreases, p = 0.04
a 63 % reduction in PMI for stable angina patients (OR = 0.37, 95 % CI: 0.14-0.97, P = 0.04; I2 = 81 %)
PMID 26306625 · one of two readings recorded this
PMI, pooled
decreases, p = 0.00001
a 66 % relative reduction in the statin naïve group (OR = 0.34, 95 % CI: 0.24-0.49, P < 0.00001; I2 = 0 %)
PMID 26306625 · one of two readings recorded this
post-PCI TIMI flow grade 3
increases, p = 0.02
The overall outcome indicated that RSV preloading lead to a 61 % relative increase in post-PCI TIMI flow grade 3 (OR = 1.61, 95 % CI: 1.09-2.38, P = 0.02; Fig. 3)
PMID 26306625 · one of two readings recorded this
publication bias (Egger's regression), MACE funnel plot
no effect, p = 0.139
Funnel plots for MACE were generated using a fixed effect model (P = 0.139 > 0.05)
PMID 26306625 · one of two readings recorded this
publication bias (Egger's regression), PMI funnel plot
no effect, p = 0.273
for PMI were generated using a random effects model (P = 0.273 > 0.05)
PMID 26306625 · one of two readings recorded this
spontaneous MI during follow-up (event counts)
decreases, p = 0.02
Spontaneous MI | 7(0.7 %) | 20(2.1 %) | 0.02
PMID 26306625 · one of two readings recorded this
spontaneous MI during follow-up (event counts)
decreases, p = 0.01
Spontaneous MI | 12(0.9 %) | 27(2.2 %) | 0.01
PMID 26306625 · one of two readings recorded this
spontaneous MI during follow-up (event counts)
decreases, p = 0.005
Spontaneous MI | 10(0.8 %) | 26(2.3 %) | 0.005
PMID 26306625 · one of two readings recorded this
spontaneous MI during follow-up (event counts)
no effect, p = 0.13
Spontaneous MI | 2(0.8 %) | 5(3.0 %) | 0.13
PMID 26306625 · one of two readings recorded this
spontaneous MI during follow-up (event counts)
no effect, p = 0.34
Spontaneous MI | 5(1.4 %) | 7(2.4 %) | 0.34
PMID 26306625 · one of two readings recorded this
spontaneous MI during follow-up (event counts)
decreases, p = 0.02
Spontaneous MI | 8(0.8 %) | 21(2.2 %) | 0.02
PMID 26306625 · one of two readings recorded this
TVR during follow-up (event counts)
decreases, p = 0.01
TVR | 19(2.0 %) | 37(3.9 %) | 0.01
PMID 26306625 · one of two readings recorded this
TVR during follow-up (event counts)
decreases, p = 0.002
TVR | 24(1.8 %) | 49(4.0 %) | 0.002
PMID 26306625 · one of two readings recorded this
TVR during follow-up (event counts)
decreases, p = 0.002
TVR | 23(1.9 %) | 47(4.2 %) | 0.002
PMID 26306625 · one of two readings recorded this
TVR during follow-up (event counts)
no effect, p = 0.09
TVR | 3(1.2 %) | 7(4.2 %) | 0.09
PMID 26306625 · one of two readings recorded this
TVR during follow-up (event counts)
no effect, p = 0.05
TVR | 5(1.4 %) | 12(4.2 %) | 0.05
PMID 26306625 · one of two readings recorded this
TVR during follow-up (event counts)
decreases, p = 0.008
TVR | 20(2.1 %) | 40(4.2 %) | 0.008
PMID 26306625 · one of two readings recorded this
cTnT after PCI
decreases
the level of cTnT at 24 h after PCI (SMD = -1.93, 95%CI -2.28 ~ -1.59, P = 0.000)
PMID 28231287 · one of two readings recorded this
HDL-C after PCI
increases
the loading dose of rosuvastatin can significantly increase the level of HDL-C at 48 h after PCI (SMD = 0.61, 95%CI 0.34 ~ 0.88, P = 0.000)
PMID 28231287 · one of two readings recorded this
hs-CRP after PCI at 24 h, 48 h and 4 weeks; also LDL-C, HDL-C, TG, TC, cTnT; rosuvastatin 20 mg/day loading versus 10 mg/day conventional dose
decreases, SMD -0.65 at 24 h, 95% CI -0.84 to -0.47
Not recorded as a finding: the comparison was against another active treatment
Meta-analysis results showed that compared with the that of the conventional dose group, the loading dose of rosuvastatin can significantly reduce the hs-CRP level after PCI, including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000), 48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11,P = 0.006) and 4 weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000).
PMID 28231287 · one of two readings recorded this
hs-CRP after PCI
decreases
including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000)
PMID 28231287 · one of two readings recorded this
hs-CRP after PCI
decreases
4 weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000)
PMID 28231287 · one of two readings recorded this
hs-CRP after PCI
decreases, p = 0.006
48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11,P = 0.006)
PMID 28231287 · one of two readings recorded this
hs-CRP, LDL-C, HDL-C, triglycerides, total cholesterol and cTnT after PCI, rosuvastatin 20 mg/day loading dose versus 10 mg/day conventional dose, pooled SMD
decreases, hs-CRP at 24 hours SMD = -0.65, 95% CI -0.84 ~ -0.47
Not recorded as a finding: the comparison was against another active treatment
Meta-analysis results showed that compared with the that of the conventional dose group, the loading dose of rosuvastatin can significantly reduce the hs-CRP level after PCI, including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000), 48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11,P = 0.006) and 4 weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000).
PMID 28231287 · one of two readings recorded this
LDL-C after PCI
decreases
the level of LDL-C at 30 d after PCI (SMD = -0.89, 95%CI -1.10 ~ -0.69, P = 0.000)
PMID 28231287 · one of two readings recorded this
LDL-C after PCI
no effect, p = 0.513
but cannot reduce the level of LDL-C at 48 h after PCI (P = 0.513)
PMID 28231287 · one of two readings recorded this
publication bias (Egger's test), hs-CRP change after PCI
unclear, p = 0.014
Egger’s test demonstrated obvious publication bias under the change of hs-CRP after PCI (P = 0.014)
PMID 28231287 · one of two readings recorded this
publication bias (Egger's test), LDL-C, HDL-C and cTnT change after PCI
unclear, p = 0.003
and the change of LDL-C,HDL-C and cTnT after PCI (P = 0.003)
PMID 28231287 · one of two readings recorded this
publication bias (Egger's test), TG and TC change after PCI
no effect, p = 0.841
Egger’s test did not exhibit obvious publication bias under the change of TG and TC after PCI (P = 0.841)
PMID 28231287 · one of two readings recorded this
total cholesterol (TC) after PCI
no effect
but cannot reduce the level of TG at 48 h after PCI and the level of TC at 24 h after PCI
PMID 28231287 · one of two readings recorded this
total cholesterol (TC) after PCI
decreases
the level of TC at 30 d after PCI (SMD = -0.77, 95%CI -0.98 ~ -0.56, P = 0.000)
PMID 28231287 · one of two readings recorded this
total cholesterol (TC) after PCI
decreases, p = 0.043
the level of TC at 48 h after PCI (SMD = -0.35, 95%CI -0.68 ~ -0.01, P = 0.043)
PMID 28231287 · one of two readings recorded this
triglycerides (TG) after PCI
decreases
the level of TG at 30 d after PCI (SMD = -0.94, 95%CI -1.17 ~ -0.71, P = 0.000)
PMID 28231287 · one of two readings recorded this
triglycerides (TG) after PCI
no effect
but cannot reduce the level of TG at 48 h after PCI and the level of TC at 24 h after PCI
PMID 28231287 · one of two readings recorded this
cystatin C (CysC) after operation
decreases, p = 0.03
CysC 24 hours: SMD = −0.54, 95% CI −1.02 to −0.05, P =.03
PMID 28682890 · one of two readings recorded this
cystatin C (CysC) after operation
decreases, p = 0.004
CysC 72 hours: SMD = −0.66, 95% CI −1.11 to −0.21, P =.004
PMID 28682890 · one of two readings recorded this
hs-CRP after operation
decreases, p = 0.01
hs-CRP 24 hours: SMD = −0.54, 95% CI −0.96 to −0.12, P =.01
PMID 28682890 · one of two readings recorded this
hs-CRP after operation
decreases, p = 0.0001
hs-CRP 72 hours: SMD = −1.01, 95% CI −1.45 to −0.56, P <.0001
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.0001
the same effect was seen in other comparisons between moderate or high-dose rosuvastatin treatment group with placebo group (RR = 0.49, 95% CI 0.35–0.69, P <.0001; I2 = 17%)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.0001
studies that received moderate or high-dose rosuvastatin treatment had significantly reduced incidence of CIN than those that received low-dose rosuvastatin treatment (RR = 0.40, 95% CI 0.27–0.59, P <.0001; I2 = 0%)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.006
moderate (20 mg) or high dose (≥40 mg) rosuvastatin significantly reduced the incidence of CIN compared with the control (RR = 0.39, 95% CI 0.29–0.54, P <.0001, RR = 0.56, 95% CI 0.37–0.85, P =.006, respectively)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.0001
moderate (20 mg) or high dose (≥40 mg) rosuvastatin significantly reduced the incidence of CIN compared with the control (RR = 0.39, 95% CI 0.29–0.54, P <.0001, RR = 0.56, 95% CI 0.37–0.85, P =.006, respectively)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.0009
in ACS patients undergoing PCI (RR = 0.52, 95% CI 0.35–0.76, P =.0009; I2 = 0%)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.03
indicated that moderate or high-dose rosuvastatin treatment also significantly reduced risk of CIN than control group (RR = 0.53, 95% CI 0.30–0.93, P =.03; I2 = 11%)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.01
seen in patients with DM (RR = 0.51, 95% CI 0.31–0.86, P =.01; I2 = 0%)
PMID 28682890 · one of two readings recorded this
incidence of CIN
decreases, p = 0.0001
in studies that received contrast volume ≥110 mL (RR = 0.43, 95% CI 0.32–0.58, P <.0001; I2 = 0%)
PMID 28682890 · one of two readings recorded this
incidence of contrast-induced nephropathy (CIN)
decreases, p = 0.0001, n = 2673
Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P <.0001)
PMID 28682890 · one of two readings recorded this
incidence of contrast-induced nephropathy (SCr rise of 25% or 44.2 umol/L within 2 to 5 days), moderate or high-dose rosuvastatin versus low-dose rosuvastatin or placebo, pooled RR; also SCr, cystatin C, hs-CRP, urine microalbumin
decreases, RR = 0.45, 95% CI 0.35-0.58
Not recorded as a finding: the comparison was against another active treatment
Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P <.0001).
PMID 28682890 · one of two readings recorded this
incidence of contrast-induced nephropathy, SCr rise of 25% or 44.2 umol/L within 2 to 5 days; moderate or high-dose rosuvastatin versus low-dose rosuvastatin or placebo pooled
decreases, RR 0.45, 95% CI 0.35-0.58
Not recorded as a finding: the comparison was against another active treatment
Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P <.0001).
PMID 28682890 · one of two readings recorded this
serum creatinine (SCr) after operation
no effect, p = 0.06
SCr 24 hours: SMD = −0.30, 95% CI −0.62 to 0.01, P =.06
PMID 28682890 · one of two readings recorded this
serum creatinine (SCr) after operation
decreases, p = 0.02
SCr 72 hours: SMD = −0.27, 95% CI −0.49 to −0.05, P =.02
PMID 28682890 · one of two readings recorded this
urine microalbumin (mALB) after operation
decreases, p = 0.01
mALB 24 hours: SMD = −0.73, 95% CI −1.32 to −0.15, P =.01
PMID 28682890 · one of two readings recorded this
urine microalbumin (mALB) after operation
no effect, p = 0.09
mALB 72 hours: SMD = −0.52, 95% CI −1.12 to 0.08, P =.09
PMID 28682890 · one of two readings recorded this
incidence of CI-AKI
decreases, p = 0.04
Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004), as compared with that in the placebo group
PMID 30464400 · one of two readings recorded this
incidence of CI-AKI
decreases, p = 0.004
Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004), as compared with that in the placebo group
PMID 30464400 · one of two readings recorded this
incidence of contrast-induced acute kidney injury (CI-AKI/CIN) after rosuvastatin pretreatment versus placebo, pooled odds ratio; no named criteria set (KDIGO, AKIN, RIFLE) stated in Methods or Results
decreases, OR 0.53, 95% CI 0.40-0.71
Not recorded as a finding: the paper never states the instrument the node requires
The data pooled from all five articles included in our research showed that the risk of CI-AKI (OR: 0.53, 95% CI: 0.40–0.71, P<0.0001) in the atorvastatin treatment group was lower than that in the control group.
PMID 30464400 · one of two readings recorded this
incidence of contrast-induced acute kidney injury (CI-AKI/CIN), pooled OR across five RCTs of rosuvastatin pretreatment before coronary angiography; no KDIGO/AKIN criteria set stated
decreases, CKD subgroup OR 0.45, 95% CI 0.21-0.95, p = 0.04
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004), as compared with that in the placebo group.
PMID 30464400 · one of two readings recorded this
incidence of contrast-induced acute kidney injury (CI-AKI), pooled
decreases, p = 0.0001
The data pooled from all five articles included in our research showed that the risk of CI-AKI (OR: 0.53, 95% CI: 0.40–0.71, P<0.0001) in the atorvastatin treatment group was lower than that in the control group
PMID 30464400 · one of two readings recorded this
venous thromboembolism (deep vein thrombosis or pulmonary embolism) incidence during follow-up, pooled individual participant data from two RCTs
decreases, hazard ratio 0.53, 95% CI 0.37-0.75, n = 30507
Not recorded as a finding: this platform holds no node for the endpoint
In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).
PMID 33705531 · one of two readings recorded this
venous thromboembolism (deep vein thrombosis or pulmonary embolism) incidence
decreases, hazard ratio 0.53, 95% CI 0.37-0.75
Not recorded as a finding: this platform holds no node for the endpoint
In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).
PMID 33705531 · one of two readings recorded this
venous thromboembolism (deep vein thrombosis or pulmonary embolism)
decreases, hazard ratio 0.53, 95% CI 0.37-0.75, n = 30507
In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).
PMID 33705531 · both readings recorded this
venous thromboembolism (deep vein thrombosis or pulmonary embolism)
decreases, n = 30507
In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75)
PMID 33705531 · one of two readings recorded this
venous thromboembolism, interaction of rosuvastatin effect across demographic, CVD risk factor and cancer-history subgroups
no effect, p = 0.05
No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups)
PMID 33705531 · one of two readings recorded this
venous thromboembolism, subgroup interaction testing
no effect
No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups).
PMID 33705531 · one of two readings recorded this
systolic blood pressure (setting unspecified)
MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08, p = 0.08
Not recorded as a finding: The sentence negates only one tail ('not associated with a significant reduction'), and no sentence in the paper states a two-sided absence of difference for SBP, so no direction is recordable per the one-sided-negation rule.
However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).
PMID 34818350 · one of two readings recorded this
systolic blood pressure (SBP) change from baseline
MD = -2.27 mmHg; 95% CI = -4.79 to 0.25, p = 0.08
However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).
PMID 34818350 · one of two readings recorded this
systolic blood pressure (SBP), pooled mean difference across RCTs
MD = −2.27 mmHg; 95% CI = −4.79 to 0.25, p = 0.08
Not recorded as a finding: the sentence states only a one-sided 'not associated with a significant reduction' (ADR rule 1a); no two-sided no-difference statement exists in Results to support no_effect, so direction is not recordable
However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).
PMID 34818350 · one of two readings recorded this
systolic blood pressure (SBP)
MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08, p = 0.08
However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).
PMID 34818350 · one of two readings recorded this
composite adverse events
no effect, odds ratio 0.50; 95% CI 0.15 to 1.72, p = 0.27
Based on three studies (I2=0%; p for heterogeneity=0.84), the risk of composite AEs (common effect model; odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the monotherapy group.
PMID 38154476 · one of two readings recorded this
composite adverse events
no effect, odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27, p = 0.27
Based on three studies (I2=0%; p for heterogeneity=0.84), the risk of composite AEs (common effect model; odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the monotherapy group.
PMID 38154476 · one of two readings recorded this
percentage HDL-C elevation
no effect, p = 0.86
Likewise, the percentages HDL-C elevation (I2=0%; p for heterogeneity=0.85) were not different between the two groups (common effect model; 95% CI -0.20 to 0.17; p=0.86).
PMID 38154476 · one of two readings recorded this
percentage HDL-C elevation
no effect, 95% CI -0.20 to 0.17; p=0.86, p = 0.86
Likewise, the percentages HDL-C elevation (I2=0%; p for heterogeneity=0.85) were not different between the two groups (common effect model; 95% CI -0.20 to 0.17; p=0.86).
PMID 38154476 · one of two readings recorded this
percentage LDL-C reduction (primary outcome)
no effect, SMD 0.08; 95% CI -0.09 to 0.26; p=0.35, p = 0.35
Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].
PMID 38154476 · one of two readings recorded this
percentage LDL-C reduction
no effect, SMD 0.08; 95% CI -0.09 to 0.26, p = 0.35
Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].
PMID 38154476 · one of two readings recorded this
percentage reduction in LDL-C (primary outcome), plus TC, TG, HDL-C elevation, and composite adverse events, comparing 5 mg rosuvastatin/10 mg ezetimibe with 20 mg rosuvastatin monotherapy
no effect, SMD 0.08; 95% CI -0.09 to 0.26; p=0.35, p = 0.35
Not recorded as a finding: the comparison was against another active treatment
Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].
PMID 38154476 · one of two readings recorded this
percentage reduction in LDL-C with rosuvastatin, compared between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin monotherapy
no effect, SMD 0.08; 95% CI -0.09 to 0.26, p = 0.35
Not recorded as a finding: the comparison was against another active treatment
Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].
PMID 38154476 · one of two readings recorded this
percentage total cholesterol (TC) reduction
increases, SMD 0.22; 95% CI 0.04 to 0.41, p = 0.02
Based on four studies (I2=47%; p for heterogeneity=0.13), the percentage TC reduction was greater in the 5 mg rosuvastatin/10 mg ezetimibe group (common effect model; SMD 0.22; 95% CI 0.04 to 0.41; p=0.02).
PMID 38154476 · one of two readings recorded this
percentage total cholesterol (TC) reduction
decreases, SMD 0.22; 95% CI 0.04 to 0.41; p=0.02, p = 0.02
Based on four studies (I2=47%; p for heterogeneity=0.13), the percentage TC reduction was greater in the 5 mg rosuvastatin/10 mg ezetimibe group (common effect model; SMD 0.22; 95% CI 0.04 to 0.41; p=0.02).
PMID 38154476 · one of two readings recorded this
percentage triglyceride (TG) reduction
no effect, SMD -0.27; 95% CI -0.84 to 0.30, p = 0.36
The percentage TG reduction of the two regimens (I2=89%; p for heterogeneity<0.01) did not differ (random effect model; SMD -0.27; 95% CI -0.84 to 0.30; p=0.36).
PMID 38154476 · one of two readings recorded this
percentage triglyceride (TG) reduction
no effect, SMD -0.27; 95% CI -0.84 to 0.30; p=0.36, p = 0.36
The percentage TG reduction of the two regimens (I2=89%; p for heterogeneity<0.01) did not differ (random effect model; SMD -0.27; 95% CI -0.84 to 0.30; p=0.36).
PMID 38154476 · one of two readings recorded this
LDL-C change
decreases, MD -8.06, 95% CI [-9.48, -6.64]
Meta-analysis showed that the combination group improved LDL-C better than the monotherapy group, and the difference was statistically significant (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05).
PMID 39536001 · one of two readings recorded this
LDL-C
decreases, MD -8.06, 95% CI [-9.48, -6.64] p < 0.05
Meta-analysis showed that the combination group improved LDL-C better than the monotherapy group, and the difference was statistically significant (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05).
PMID 39536001 · one of two readings recorded this
total cholesterol (TC)
decreases, MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05
The findings demonstrated a statistically significant difference in TC improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05].
PMID 40082758 · one of two readings recorded this
HDL-C percentage change, CA+AA vs CC genotype
no effect, MD = -2.22, 95% CI (-19.87, 15.43), p = 0.81
The findings demonstrated that there was no statistically significant difference in the level of HDL-C improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81].
PMID 40082758 · one of two readings recorded this
HDL-C
no effect, MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81, p = 0.81
The findings demonstrated that there was no statistically significant difference in the level of HDL-C improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81].
PMID 40082758 · one of two readings recorded this
total cholesterol (TC) percentage change, CA+AA vs CC genotype
decreases, MD = -7.15, 95% CI (-8.78, -5.53)
The findings demonstrated a statistically significant difference in TC improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05].
PMID 40082758 · one of two readings recorded this
triglycerides (TG) percentage change, CA+AA vs CC genotype
decreases, MD = -7.34, 95% CI (-10.88, -3.80)
The findings demonstrated that patients with the CA + AA genotype had a statistically significant improvement in TG compared to those with the CC genotype [MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05].
PMID 40082758 · one of two readings recorded this
triglycerides (TG)
decreases, MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05
The findings demonstrated that patients with the CA + AA genotype had a statistically significant improvement in TG compared to those with the CC genotype [MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05].
PMID 40082758 · one of two readings recorded this
TNF-α
decreases
Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.
PMID 40529224 · both readings recorded this
IL-6
decreases, n = 911
Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.
PMID 40529224 · both readings recorded this
IL-8
decreases
Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.
PMID 40529224 · both readings recorded this
FEV1/FVC ratio, difference between pulmonary hypertension and non-comorbid subgroups
no effect, p = 0.44
However, the difference between the two subgroups was not statistically significant (P = 0.44, I² = 0%)
PMID 40529224 · one of two readings recorded this
FEV1/FVC ratio, pooled after sensitivity exclusion of Yao W 2020
increases
Re-analysis of the remaining seven trials yielded a heterogeneity test result of (P = 0.40, I² = 4%), with an MD of 4.99 and a 95% confidence interval of [4.05, 5.92]
PMID 40529224 · one of two readings recorded this
FEV1/FVC ratio, pooled
increases, p = 0.0004, n = 737
The meta-analysis results indicated that the combined effect size MD was 6.36, with a 95% confidence interval of [2.86, 9.86], and the difference was statistically significant (Z = 3.56, P = 0.0004)
PMID 40529224 · one of two readings recorded this
FEV1/FVC ratio
increases, n = 911
Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).
PMID 40529224 · both readings recorded this
FEV1, pooled after sensitivity exclusion of Yao W 2020 and Yu H 2017
increases
Re-analysis of the remaining four trials yielded a heterogeneity test result of (P = 0.27, I² = 24%), with an MD of 0.35 and a 95% confidence interval of [0.31, 0.40]
PMID 40529224 · one of two readings recorded this
FEV1, pooled
increases, p = 0.0006, n = 616
The meta-analysis results revealed that the combined effect size MD was 0.63, with a 95% confidence interval of [0.27, 0.99], and the difference was statistically significant (Z = 3.42, P = 0.0006)
PMID 40529224 · one of two readings recorded this
FEV1, single study Liu YQ 2023 post-treatment
increases, p = 0.003
However, post-treatment, the improvement in the experimental group was significantly superior to that in the control group, with a significant difference observed between the two groups (t = 3.252, P = 0.003)
PMID 40529224 · one of two readings recorded this
forced expiratory volume in 1 second (FEV1)
increases
Not recorded as a finding: a node exists but the paper states a different instrument or population
Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).
PMID 40529224 · one of two readings recorded this
forced expiratory volume in 1 second (FEV1)
increases
Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).
PMID 40529224 · one of two readings recorded this
forced vital capacity (FVC), pooled
increases, p = 0.00001, n = 378
Meta-analysis results demonstrated that the combined effect size MD was 0.60, with a 95% confidence interval of [0.48, 0.73], and the difference was statistically significant (Z = 9.18, P < 0.00001)
PMID 40529224 · one of two readings recorded this
forced vital capacity (FVC), single study Liu YQ 2023 post-treatment
increases, p = 0.033
However, post-treatment, the improvement in the experimental group was significantly superior to that in the control group, with a significant difference observed between the two groups (t = 2.187, P = 0.033)
PMID 40529224 · one of two readings recorded this
forced vital capacity (FVC)
increases
Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).
PMID 40529224 · both readings recorded this
galectin-3 (Gal-3), pooled
decreases, p = 0.00001, n = 219
Similarly, for Gal-3, the combined effect size was MD = −6.01, with a 95% confidence interval of [−6.75, −5.28], also demonstrating statistical significance (Z = 16.01, P < 0.00001)
PMID 40529224 · one of two readings recorded this
galectin-3 (Gal-3)
decreases
Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.
PMID 40529224 · both readings recorded this
hs-CRP, change from pre- to post-treatment, single study Chen Y 2013
decreases, p = 0.05
The findings of Chen Y 2013 demonstrated a statistically significant difference in the change from pre-treatment to post-treatment between the experimental and control groups, with a mean difference of 19.49 ± 7.10 (P < 0.05)
PMID 40529224 · one of two readings recorded this
hs-CRP, pooled MD across five RCTs of adjunctive rosuvastatin in AECOPD
decreases, MD -4.54, 95% CI [-5.02, -4.06]
Not recorded as a finding: the supporting sentence never names the compound
The meta-analysis revealed that the combined effect size MD was −4.54, with a 95% confidence interval of [−5.02, −4.06], demonstrating statistical significance (Z = 18.64, P < 0.00001), as illustrated in Figure 8.
PMID 40529224 · one of two readings recorded this
hs-CRP, pooled
decreases, p = 0.00001, n = 482
The meta-analysis revealed that the combined effect size MD was −4.54, with a 95% confidence interval of [−5.02, −4.06], demonstrating statistical significance (Z = 18.64, P < 0.00001)
PMID 40529224 · one of two readings recorded this
hs-CRP
decreases, n = 911
Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.
PMID 40529224 · both readings recorded this
IL-6, pooled
decreases, p = 0.00001, n = 140
The meta-analysis indicated that the combined effect size MD was −13.58, with a 95% confidence interval of [−17.52, −9.64], demonstrating statistical significance (Z = 6.76, P < 0.00001)
PMID 40529224 · one of two readings recorded this
IL-8, pooled
decreases, p = 0.01, n = 134
The meta-analysis revealed that the combined effect size MD was −38.87, with a 95% confidence interval of [−68.27, −9.48], indicating statistical significance (Z = 2.59, P = 0.010)
PMID 40529224 · one of two readings recorded this
incidence of adverse reactions, single study
decreases, p = 0.05
Liu demonstrated that the incidence of adverse reactions in the observation group was significantly lower than in the control group (χ² = 4.0556, P < 0.05)
PMID 40529224 · one of two readings recorded this
neutrophil elastase (NE), pooled
decreases, p = 0.00001, n = 219
The meta-analysis results indicated that the combined effect size for NE was MD = −3.26, with a 95% confidence interval of [−3.93, −2.59], showing statistical significance (Z = 9.53, P < 0.00001)
PMID 40529224 · one of two readings recorded this
neutrophil elastase (NE)
decreases, n = 911
Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.
PMID 40529224 · both readings recorded this
peak expiratory flow (PEF), pooled
increases, p = 0.00001, n = 388
The meta-analysis results showed that the combined effect size MD was 0.67, with a 95% confidence interval of [0.61, 0.73], and the difference was statistically significant (Z = 21.64, P < 0.00001)
PMID 40529224 · one of two readings recorded this
peak expiratory flow (PEF), single study Liu YQ 2023 post-treatment
increases, p = 0.029
However, post-treatment, the improvement in the experimental group was significantly superior to that in the control group, with a notable difference between the two groups (t = 2.240, P = 0.029)
PMID 40529224 · one of two readings recorded this
peak expiratory flow (PEF)
increases
Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).
PMID 40529224 · both readings recorded this
publication bias (Egger's test), FEV1/FVC outcome
unclear, p = 0.004
Egger’s test results (z = 2.88, P = 0.0040) indicated the presence of publication bias
PMID 40529224 · one of two readings recorded this
TNF-α, single studies Yao W 2020 and Huan YF 2013 (not pooled)
decreases, p = 0.05
The findings from Yao W 2020 and Huan YF 2013 both demonstrated that the experimental group significantly reduced TNF-α values compared to the control group (P < 0.05)
PMID 40529224 · one of two readings recorded this
Baseline-ECG heart rate
no effect, p = 0.091, n = 466
Heart rate (bpm) | 71.83 ± 12.20 | 73.77 ± 12.51 | 0.091
PMID 40890448 · one of two readings recorded this
Baseline QT interval
no effect, p = 0.874, n = 466
QT interval (ms) | 391.89 ± 38.51 | 392.43 ± 34.83 | 0.874
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, age (per 10 years)
increases, p = 0.007, n = 466
Age | 1.68 (1.30–2.18) | < 0.001 | 1.45 (1.11–1.91) | 0.007
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, age (per 10 years)
increases, p = 0.001, n = 466
Age | 1.68 (1.30–2.18) | < 0.001 | 1.45 (1.11–1.91) | 0.007
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, atrial fibrillation
increases, p = 0.014, n = 466
Atrial fibrillation | 4.92 (2.24–10.80) | < 0.001 | 2.89 (1.24–6.74) | 0.014
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, atrial fibrillation
increases, p = 0.001, n = 466
Atrial fibrillation | 4.92 (2.24–10.80) | < 0.001 | 2.89 (1.24–6.74) | 0.014
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, creatinine
increases, p = 0.003, n = 466
Creatinine | 1.11 (1.01–1.22) | 0.003 | -- | --
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, heart failure
increases, p = 0.001, n = 466
Heart failure | 5.25 (2.61–10.58) | < 0.001 | 3.85 (1.83–8.12) | < 0.001
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, heart failure
increases, p = 0.001, n = 466
Heart failure | 5.25 (2.61–10.58) | < 0.001 | 3.85 (1.83–8.12) | < 0.001
PMID 40890448 · one of two readings recorded this
Baseline QT prolongation, LVDd
increases, p = 0.001, n = 466
LVDd | 1.19 (1.12–1.26) | < 0.001 | -- | --
PMID 40890448 · one of two readings recorded this